BR0211317A - Sistema para a liberação controlada de uma droga por meio de retenção gástrica - Google Patents

Sistema para a liberação controlada de uma droga por meio de retenção gástrica

Info

Publication number
BR0211317A
BR0211317A BR0211317-1A BR0211317A BR0211317A BR 0211317 A BR0211317 A BR 0211317A BR 0211317 A BR0211317 A BR 0211317A BR 0211317 A BR0211317 A BR 0211317A
Authority
BR
Brazil
Prior art keywords
drug
gastric retention
nucleus
controlled release
release
Prior art date
Application number
BR0211317-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Kamlesh Mohanlal Dudhara
Nitin Bhalachand Dharmadhikari
Vaishali Vijay Dhavse
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of BR0211317A publication Critical patent/BR0211317A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR0211317-1A 2001-07-04 2002-07-04 Sistema para a liberação controlada de uma droga por meio de retenção gástrica BR0211317A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN612MU2001 2001-07-04
PCT/IN2002/000144 WO2003011255A1 (en) 2001-07-04 2002-07-04 Gastric retention controlled drug delivery system

Publications (1)

Publication Number Publication Date
BR0211317A true BR0211317A (pt) 2004-12-14

Family

ID=32051199

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211317-1A BR0211317A (pt) 2001-07-04 2002-07-04 Sistema para a liberação controlada de uma droga por meio de retenção gástrica

Country Status (17)

Country Link
US (2) US7776345B2 (enExample)
EP (2) EP2238975B1 (enExample)
JP (2) JP4994570B2 (enExample)
KR (1) KR20040018394A (enExample)
CN (1) CN1520286B (enExample)
AT (1) ATE477795T1 (enExample)
AU (1) AU2002355686B2 (enExample)
BR (1) BR0211317A (enExample)
CA (1) CA2452738C (enExample)
DE (1) DE60237372D1 (enExample)
ES (1) ES2398348T3 (enExample)
HU (1) HUP0500795A3 (enExample)
MX (1) MXPA03012041A (enExample)
PL (1) PL370793A1 (enExample)
RU (1) RU2325152C2 (enExample)
WO (1) WO2003011255A1 (enExample)
ZA (1) ZA200400799B (enExample)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
AU2002310409C1 (en) 2001-06-11 2008-04-17 Xenoport, Inc. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
BR0211317A (pt) * 2001-07-04 2004-12-14 Sun Pharmaceutical Ind Ltd Sistema para a liberação controlada de uma droga por meio de retenção gástrica
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
AU2002319898A1 (en) * 2002-06-04 2003-12-19 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
MY142204A (en) 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
AU2004267100B2 (en) 2003-08-20 2010-10-07 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
JP5686494B2 (ja) * 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
JP2007513975A (ja) * 2003-12-12 2007-05-31 ペンウェスト ファーマシューティカルズ カンパニー 徐放性トルセミド剤形
WO2005060942A1 (en) * 2003-12-19 2005-07-07 Aurobindo Pharma Ltd Extended release pharmaceutical composition of metformin
TW200533391A (en) * 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
US20060018957A1 (en) 2004-07-26 2006-01-26 Lerner E I Pharmaceutical dosage forms including rasagiline
UA88477C2 (ru) 2004-08-13 2009-10-26 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
FR2874325B1 (fr) * 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
DE102004042139B4 (de) * 2004-08-31 2009-06-10 Aristocon Verwaltungs- Gmbh Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit
WO2006044202A2 (en) * 2004-10-19 2006-04-27 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid
US7566738B2 (en) 2004-11-03 2009-07-28 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
US7494985B2 (en) 2004-11-03 2009-02-24 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
EP1811986B1 (en) 2004-11-04 2014-03-26 XenoPort, Inc. Gabapentin prodrug sustained release oral dosage forms
JP5175553B2 (ja) * 2005-02-01 2013-04-03 エミスフェアー・テクノロジーズ・インク 胃内滞留および制御放出型送達系
EP1690540A1 (en) * 2005-02-15 2006-08-16 Neuro3D Composition comprising ocaperidone
ES2403069T3 (es) * 2005-02-22 2013-05-13 Sun Pharma Advanced Research Company Ltd Composición oral de liberación controlada que contiene levetiracetam
US7815942B2 (en) * 2005-02-23 2010-10-19 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
ATE396710T1 (de) * 2005-07-19 2008-06-15 Ethypharm Sa Gastroretentive zusammensetzungen und verfahren zur herstellung
EP1957052A2 (en) * 2005-10-25 2008-08-20 Pharmascience Inc. A gastric retention drug delivery system
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
AU2007201808B8 (en) * 2006-04-26 2013-09-05 Sun Pharmaceutical Advanced Research Company Ltd A method for alleviating signs and symptoms of spasticity
US8703191B2 (en) * 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
PT2049123E (pt) 2006-08-03 2013-03-06 Horizon Pharma Ag Tratamento de doença reumatóide com glucocorticóide de libertação retardada
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
WO2008022171A1 (en) * 2006-08-17 2008-02-21 Boehringer Ingelheim International Gmbh Methods of using aryl sulfonyl compounds effective as soluble epoxide hydrolase inhibitors
WO2008033572A1 (en) 2006-09-15 2008-03-20 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
RU2487703C2 (ru) * 2006-09-26 2013-07-20 Новартис Аг Фармацевтические композиции, включающие модулятор s1р
CA2672602C (en) 2006-12-18 2014-05-20 Electronic Dietary Foods Inc. Device for delivery of a substance
WO2008080092A2 (en) * 2006-12-22 2008-07-03 Ironwood Pharmaceuticals, Inc. Compositions comprising bile acid sequestrants for treating esophageal disorders
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
CN101011393B (zh) * 2007-02-16 2010-10-06 广州柏赛罗药业有限公司 厄贝沙坦胃内滞留型缓释药物组合物
DE102007026037A1 (de) 2007-06-04 2008-12-11 Lts Lohmann Therapie-Systeme Ag Gastroretentives System mit Alginat-Körper
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US20100035886A1 (en) * 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
HUP0700469A2 (en) * 2007-07-09 2009-04-28 Richter Gedeon Nyrt Floating pharmaceutical composition of sustained release containing metronidazol
MX2010001071A (es) * 2007-07-27 2010-03-09 Depomed Inc Formas de dosificacion retentivas gastricas pulsatiles.
WO2009023761A2 (en) * 2007-08-14 2009-02-19 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions comprising ropinirole
WO2009069089A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Levetiracetam controlled release composition
EP2065038A1 (en) * 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
US20090196935A1 (en) * 2008-02-01 2009-08-06 Ahmed Salah U Pharmaceutical Capsules Comprising Extended Release Dipyridamole Pellets
US9457048B2 (en) * 2008-02-05 2016-10-04 Wellosophy Corporation Absorbent ingestible agents and associated methods of manufacture and use
DK2276473T3 (en) 2008-04-18 2017-01-09 Intec Pharma Ltd GASTRORETENTIV drug TO carbidopa / levodopa
ZA200903858B (en) * 2008-06-19 2013-10-30 Univ Of Witwatesrand Johannesburg Pharmaceutical dosage form
US20110129433A1 (en) * 2008-06-26 2011-06-02 Ironwood Pharmaceuticals, Inc. Compositions and Methods for Treating or Preventing Gastrointestinal Disorders and GERD-Related Respiratory Disorders
EP2299983A4 (en) * 2008-07-24 2012-10-10 Handa Pharmaceuticals Llc ATYPICAL ANTIPSYCHOTIC FORMULATION STABILIZED
ES2740360T3 (es) 2008-08-15 2020-02-05 Assertio Therapeutics Inc Composiciones farmacéuticas de retención gástrica para el tratamiento y la prevención de trastornos del SNC
WO2010064139A2 (en) 2008-12-04 2010-06-10 Intec Pharma Ltd. Zaleplon gastroretentive drug delivery system
JP5783908B2 (ja) 2008-12-19 2015-09-24 スパーナス ファーマシューティカルズ インコーポレイテッド 攻撃性を治療する方法
EP2391369A1 (en) * 2009-01-26 2011-12-07 Nitec Pharma AG Delayed-release glucocorticoid treatment of asthma
EP2564836A1 (en) * 2009-05-20 2013-03-06 Ranbaxy Laboratories Limited Controlled release lamotrigine formulations
KR101057640B1 (ko) * 2009-05-27 2011-08-18 (주)다산메디켐 발포성 층을 포함하는 다층 정제
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
US20110104273A1 (en) * 2009-11-05 2011-05-05 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of phenylephrine
US9943489B2 (en) * 2010-02-03 2018-04-17 Pharmatwob Ltd. Extended release formulations of rasagiline and uses thereof
WO2011101866A2 (en) * 2010-02-17 2011-08-25 Sun Pharma Advanced Research Company Ltd., A method of treating a disease condition susceptible to baclofen therapy
EP3572074B1 (en) 2010-03-31 2021-01-06 Supernus Pharmaceuticals, Inc. Stabilized formulations of molindone
KR101270751B1 (ko) * 2010-05-06 2013-06-07 (주)비씨월드제약 위 체류 및 방출 조절을 위한 조성물
EP2575798B1 (en) 2010-06-01 2017-08-09 Rubicon Research Private Limited Gastroretentive dosage forms of gaba analogs
RS54447B1 (sr) * 2011-01-20 2016-06-30 Bionevia Pharmaceuticals Inc. Modifikovano oslobađajuće kompozicije epalrestata ili njegovih derivata i postupci njihove upotrebe
AT511671A1 (de) * 2011-07-13 2013-01-15 Bischof Georg Dr Zusammensetzung zur erzeugung einer vorübergehenden okklusion des darms eines säugetiers
KR101438546B1 (ko) * 2011-08-26 2014-09-17 근화제약주식회사 프레가발린을 포함하는 서방성 제제
RU2489147C2 (ru) * 2011-08-31 2013-08-10 Людмила Петровна Лазурина Фармацевтическая антибактериальная композиция для местного применения на основе активных биометаллокомплексов
AU2012345659B2 (en) 2011-12-02 2017-09-28 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
CN102440976A (zh) * 2011-12-21 2012-05-09 南京海陵中药制药工艺技术研究有限公司 依帕司他缓释片及其制备方法
MY169068A (en) * 2012-04-18 2019-02-12 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
WO2014119836A1 (en) * 2013-01-30 2014-08-07 Daewoong Co., Ltd. Pharmaceutical composition for protecting wounds, providing hemostasis, or preventing adhesion in the gastrointestinal tract
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
FR3014692B1 (fr) * 2013-12-18 2016-01-29 Ethypharm Sa Compositions pharmaceutiques orales a retention gastrique.
WO2016001843A1 (en) * 2014-06-30 2016-01-07 Sun Pharmaceutical Industries Limited Extended-release gastroretentive tablets of voglibose
US10172800B2 (en) 2015-02-20 2019-01-08 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form with enhanced pharmacokinetics
US10987328B2 (en) 2015-02-20 2021-04-27 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US10300032B2 (en) 2015-02-20 2019-05-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
WO2016132218A1 (en) 2015-02-20 2016-08-25 Osmotica Kereskedelmi Es Szolgaltato Kft Method of administering r-baclofen in an extended release dosage form
RU2649834C1 (ru) * 2016-07-06 2018-04-04 Фармалидер С.А. Фармацевтическая композиция силденафила цитрата в форме суспензии для перорального применения
CN109689036B (zh) 2016-07-11 2026-06-19 康特拉医药股份有限公司 用于治疗早晨运动不能的脉冲药物输送系统
FR3054218B1 (fr) * 2016-07-22 2020-03-06 Universite De Rouen Procede de dedoublement de sels de baclofene
EP4755373A1 (en) 2016-09-09 2026-06-10 Azurity Pharmaceuticals, Inc. Suspensions and diluents for metronidazole and baclofen
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
EP3345591A1 (en) * 2017-01-06 2018-07-11 Oystershell NV Oral dosage form for enhanced solubilization of a poorly soluble active agent and method of preparation
WO2018127594A1 (en) * 2017-01-06 2018-07-12 Oystershell Nv Oral dosage form for enhanced solubilization of a poorly soluble active agent and method of preparation
EP3600320A4 (en) 2017-03-31 2020-12-16 Acura Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR THE SELF-REGULATED RELEASE OF ACTIVE PHARMACEUTICAL SUBSTANCES
JP6823539B2 (ja) * 2017-05-26 2021-02-03 株式会社ファンケル 胃内滞留性錠剤
WO2018232413A1 (en) * 2017-06-16 2018-12-20 Kashiv Pharma Llc Gastroretentive dosage forms for sustained drug delivery
US10987311B2 (en) * 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
US10588863B2 (en) * 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
CN111565716B (zh) * 2017-09-08 2023-06-09 因斯格尼斯疗法有限公司 使用地匹福林的方法
CN109985016B (zh) * 2017-12-29 2021-07-27 江苏恒瑞医药股份有限公司 一种非布司他的控释组合物及其制备方法
DK3609472T3 (da) * 2018-06-18 2021-04-06 Kashiv Specialty Pharmaceuticals Llc Forlænget frigivelsessammensætning indeholdende pyridostigmin
JP2021529158A (ja) * 2018-06-19 2021-10-28 ナショナル ユニバーシティー オブ シンガポールＮａｔｉｏｎａｌ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｓｉｎｇａｐｏｒｅ 様々な適応症についての生物学的利用能を向上させるための５−ヒドロキシトリプトファンの製剤
JP7034343B2 (ja) 2018-06-27 2022-03-11 アムニール コンプレックス プロダクツ リサーチ エルエルシー 自己調節性の浸透性胃保持性薬物送達システム
JP7044649B2 (ja) * 2018-06-28 2022-03-30 株式会社ファンケル 胃内浮遊錠剤
WO2020011938A1 (en) 2018-07-11 2020-01-16 Medizinische Universität Wien Glucocorticoids for the topical treatment of autoimmune gastritis
US20220031623A1 (en) * 2018-12-18 2022-02-03 DDP Specialty Electronic Materials US, Inc. A sustained release composition comprising a methylcellulose
EP3968980A1 (en) 2019-05-14 2022-03-23 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
RU2751163C9 (ru) * 2020-04-06 2021-10-20 Общество С Ограниченной Ответственностью "Ниармедик Плюс" Фармацевтическая композиция на основе макозинона для лечения туберкулеза, включая его формы с множественной и широкой лекарственной устойчивостью.
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions
MX2024006405A (es) * 2021-11-25 2024-06-05 Orexa B V Unidad de dosificacion oral gastrorretentiva que contiene un anestesico local.
CN114796142A (zh) * 2022-04-08 2022-07-29 黄山学院 萘普生胃漂浮片及其制备方法
CN115444831B (zh) * 2022-10-25 2023-08-22 南京康川济医药科技有限公司 一种依帕司他胃漂浮片及其制备方法
CN115721621A (zh) * 2022-12-16 2023-03-03 杭州剂泰医药科技有限责任公司 一种依帕司他缓释制剂
CN117137877A (zh) * 2023-10-09 2023-12-01 重庆士立德医药科技有限公司 一种巴氯芬缓释片及其制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4101650A (en) 1977-04-06 1978-07-18 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Pepstatin floating minicapsules
SE8404467D0 (sv) * 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
DE3681348D1 (de) 1985-06-11 1991-10-17 Teijin Ltd Oral-arzneizubereitung mit retardwirkung.
JPS62195323A (ja) 1986-02-24 1987-08-28 Eisai Co Ltd 胃内滞留型粒子
US4772473A (en) * 1986-06-16 1988-09-20 Norwich Eaton Pharmaceuticals, Inc. Nitrofurantoin dosage form
JPH0798742B2 (ja) 1986-07-03 1995-10-25 ゼリア新薬工業株式会社 徐放性製剤組成物
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
IL87710A (en) 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
US4892739A (en) 1988-04-25 1990-01-09 Ciba-Geigy Corporation Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having a improved core membrane adhesion properties
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
PH26730A (en) * 1988-12-30 1992-09-28 Ciba Geigy Ag Coated adhesive tablets
HU213407B (en) * 1993-12-09 1997-06-30 Egyt Gyogyszervegyeszeti Gyar Process for producing tablet with diffusive-osmotic release
DE4406424A1 (de) 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
WO1997020551A1 (en) * 1995-12-05 1997-06-12 Adcock Ingram Limited Pharmaceutical composition comprising a skeletal muscle relaxant, a non-steroidal antiinflammatory agent and an analgesic
US6271278B1 (en) * 1997-05-13 2001-08-07 Purdue Research Foundation Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties
ATE302597T1 (de) * 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
IN186245B (enExample) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
WO1999047128A1 (en) 1998-03-19 1999-09-23 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
AP1659A (en) 1998-09-14 2006-09-06 Ranbaxy Laboratories Ltd Orally administered controlled drug delivery system providing temporal and spatial control.
FR2784583B1 (fr) 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
DE69915346T2 (de) * 1998-12-17 2004-07-22 Alza Corp., Mountain View Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen
WO2000038650A1 (en) * 1998-12-23 2000-07-06 Alza Corporation Gastric retention dosage form having multiple layers
WO2001008670A2 (en) 1999-07-29 2001-02-08 Interneuron Pharmaceuticals, Inc. Methods and compositions for alleviating stuttering
AP2002002410A0 (en) 1999-08-04 2002-03-31 Ranbaxy Laboratories Ltd Hydrodynamically Balancing Oral Drug Delivery System
FR2797185B1 (fr) 1999-08-06 2001-10-26 Galenix Dev Composition pharmaceutique flottante comprenant une phase active et une phase non active
EP1095650A1 (en) * 1999-10-29 2001-05-02 Universiteit Leiden Double phase time-controlled release system
BR0211317A (pt) * 2001-07-04 2004-12-14 Sun Pharmaceutical Ind Ltd Sistema para a liberação controlada de uma droga por meio de retenção gástrica
AU2004267100B2 (en) * 2003-08-20 2010-10-07 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
AU2007201808B8 (en) 2006-04-26 2013-09-05 Sun Pharmaceutical Advanced Research Company Ltd A method for alleviating signs and symptoms of spasticity

Also Published As

Publication number Publication date
US8012496B2 (en) 2011-09-06
ES2398348T3 (es) 2013-03-15
US20100305208A1 (en) 2010-12-02
US20040180088A1 (en) 2004-09-16
AU2002355686B2 (en) 2007-11-29
MXPA03012041A (es) 2004-03-26
CA2452738A1 (en) 2003-02-13
RU2003138075A (ru) 2005-06-10
JP2010090161A (ja) 2010-04-22
CA2452738C (en) 2011-06-14
EP1411901B1 (en) 2010-08-18
DE60237372D1 (de) 2010-09-30
US7776345B2 (en) 2010-08-17
WO2003011255A1 (en) 2003-02-13
EP2238975B1 (en) 2012-12-05
CN1520286A (zh) 2004-08-11
EP1411901A1 (en) 2004-04-28
JP2004538301A (ja) 2004-12-24
HUP0500795A3 (en) 2008-04-28
CN1520286B (zh) 2010-12-01
PL370793A1 (en) 2005-05-30
RU2325152C2 (ru) 2008-05-27
JP4994570B2 (ja) 2012-08-08
ZA200400799B (en) 2005-07-27
EP2238975A1 (en) 2010-10-13
KR20040018394A (ko) 2004-03-03
ATE477795T1 (de) 2010-09-15
HUP0500795A2 (en) 2007-02-28

Similar Documents

Publication Publication Date Title
DE60237372D1 (de) Magenretentionssystem mit kontrollierter arzneimittelfreisetzung
ES2159591T3 (es) Composicion de liberacion controlada.
ES2571703T3 (es) Formulaciones de oxicodona de una vez al día
BR0007454A (pt) Dispositivos e métodos de implante comtransferência de droga biocompatìvel deliberação controlada no sistema ocular
MEP48308A (en) Tamper-resistant oral opioid agonist formulations
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
BR0107874A (pt) Implante farmacêutico para controlavelmente liberar uma droga, método para controlavelmente liberar uma droga em um indivìduo, e, método para preparar o implante
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
ES2126536B1 (es) "preparado farmaceutico para administracion intranasal y procedimientopara su produccion".
BR0009770A (pt) Derivados de bisindóis indigóides capazes de penetrarem na membrana de células, formulação farmacêutica e utilização da mesma
BR0209198A (pt) Métodos de sìntese de compostos contendo fenol
ECSP067062A (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
BRPI0709847B8 (pt) composição farmacêutica sólida de liberação rápida contendo paracetamol e carbonato de cálcio
SV2003000633A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7
BRPI0509276A (pt) medicamentos de sabor disfarçado em multiparticulados de ruptura
BR9713256A (pt) Forma de dosagem de bisacodil com revestimento polimérico múltiplo entérico para liberação colÈnica
BR0109602A (pt) Glóbulos de liberação controlada contendo estavudina
AR033688A1 (es) Composicion parenteral reconstituible
ES2176106A1 (es) Comprimido matricial de liberacion prolongada de trimetazidina tras su administracion por via oral.
CO5560554A2 (es) Composicion farmaceutica que comprende lumiracoxib
PT885014E (pt) Composicoes farmaceuticas contendo polimeros orto ester tamponados
BRPI0412697A (pt) composições farmacêuticas que apresentam um revestimento expansìvel
CL2015001086A1 (es) Combinación farmacéutica para el tratamiento y/o quimiosensibilizacion de tumores refractarios a drogas anticancerigenas
NO20071315L (no) Farmasoytisk preparat i form av en tablett inneholdende et aktivt prinsipp for opphold i magen.
BR0307320A (pt) Sistema de liberação osmótico

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: SUN PHARMACEUTICAL INDUSTRIES LTD. (IN)

Free format text: AFIM DE ATENDER A TRANSFERENCIA SOLICITADA ATRAVES DA PETICAO NO 018100009207/SP DE 17/03/2010, QUEIRA O INTERESSADO APRESENTAR A LEGALIZACAO CONSULAR DO DOCUMENTO DE CESSAO.

B25A Requested transfer of rights approved

Owner name: SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN)

Free format text: TRANSFERIDO DE: SUN PHARMACEUTICAL INDUSTRIES LTD.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 13 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]